Cargando…
Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
Thrombotic thrombocytopenic purpura (TTP) is a rare and unpredictable disease with a high mortality rate (90%) if untreated. It results from systemic microvascular thrombosis and leads to profound thrombocytopenia, hemolytic anemia and organ failure of varying severity. However, macrovascular thromb...
Autores principales: | Cilla, Nicolas, Dallemagne, Julie, Vanhove, Marie, Stordeur, Patrick, Motte, Serge, De Wilde, Virginie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430863/ https://www.ncbi.nlm.nih.gov/pubmed/32855757 http://dx.doi.org/10.14740/jh614 |
Ejemplares similares
-
Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020) -
Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021) -
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023) -
Caplacizumab in adult patients with acquired thrombotic
thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020) -
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)